WESTAT, INC. - PHASE I STUDY OF PHARMACOKINETICS, SAFETY AND ACCEPTABILITY OF A SINGLE DOSE OF PRETOMANID ADDED TO AN OPTIMIZED BACKGROUND REGIMEN IN CHILDREN WITH RIFAMPICIN RESISTANT TUBERCULOSIS IMPAACT 2034

PIID: 75N94022F00002

Signed Date: Dec 11, 2025Effective Date: Aug 3, 2022End Date: Closes in 75 days

Key Details

Dollars Obligated

$299,389

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541715 - RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Place of Performance

ROCKVILLE, MD, 208503129, CD-MD-08

Description

PHASE I STUDY OF PHARMACOKINETICS, SAFETY AND ACCEPTABILITY OF A SINGLE DOSE OF PRETOMANID ADDED TO AN OPTIMIZED BACKGROUND REGIMEN IN CHILDREN WITH RIFAMPICIN RESISTANT TUBERCULOSIS IMPAACT 2034

Contractor Information

Contractor: WESTAT, INC.

UEI: NVUWAFWQ57S5

CAGE Code: 1D075

Location: ROCKVILLE, MD

Similar Awards

NCI OPERATIONAL TASK ORDER, FY26-FY27

LEIDOS BIOMEDICAL RESEARCH INC

$327.1M

MD NET

LEIDOS BIOMEDICAL RESEARCH INC

$163.5M

ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)

LEIDOS BIOMEDICAL RESEARCH INC

$141.7M

AWARD OF THE BASE TO ST. JUDE FOR CEIRR CONTRACT 75N93021C00016. THIS CONTRACT WILL SUPPORT NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR).

ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

$103.3M

DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER (NBR)

ASCEND PERFORMANCE MATERIALS TEXAS INC

$87.7M

View Full Record on USASpending.gov